Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05087394 Recruiting - COVID-19 Clinical Trials

COVID19 Hospitilized in Clinica Pasteur of Neuquen (Argentina)

COVIDPas
Start date: March 20, 2020
Phase:
Study type: Observational [Patient Registry]

retrospective cohort (non-experimental study) of COVID 19 patients assisted in hospitalization (severe and critical) between 2020 and 2021

NCT ID: NCT05087381 Recruiting - Treatment Efficacy Clinical Trials

Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

There is an urgent need to identify effective treatments for SARS-CoV-2 infection that helps people recover quicker and reduces the need for hospital admission. The investigators develop an open, adaptive, platform trial to evaluate treatments, Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide suitable for use in the community for treating COVID-like-illness that might help people recover sooner and prevent hospitalisation.

NCT ID: NCT05087329 Recruiting - Prenatal Stress Clinical Trials

Mindfulness Practice in Pregnancy as an Intervention to Decrease Prenatal Stress During the COVID19 Pandemic

CALMS
Start date: May 5, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to examine whether a simple mindfulness intervention conducted via a virtual platform can reduce stress among pregnant women.

NCT ID: NCT05087290 Recruiting - Hypertension Clinical Trials

LOnger-term Effects of SARS-CoV-2 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)

LOCHINVAR
Start date: September 30, 2021
Phase:
Study type: Observational

The COVID-19 pandemic is the biggest medical challenge in decades. Individuals with pre-existing cardiovascular diseases have a higher risk of severe disease and death from COVID-19. The SARS-CoV-2 virus causes infection by targeting a molecule on the walls of the cells lining the lungs and the blood vessels leading to injury. There are concerns that after recovery from COVID-19, the damage sustained by these cells may have long-term consequences including high blood pressure, stroke and heart attacks. The burden of high blood pressure as a result of the pandemic is unknown and a greater understanding of COVID-19 impact on blood pressure and its underlying mechanisms is urgently needed. LOCHINVAR is based on our pilot study "COVID-19 blood pressure endothelium interaction study" (OBELIX,NCT04409847, IRAS 284453), which found that patients with normal blood pressure at the time of hospital admission with COVID-19 showed a nine-point higher blood pressure ≥12 weeks after recovery, compared to a group without COVID-19. LOCHINVAR will extend the OBELIX study aiming to establish if COVID-19 increases the risk of developing high blood pressure and investigating underlying mechanisms through detailed measurements of blood pressure, blood vessel function, hormones and chemicals in the blood, urine and stool. We will invite 150 adults without pre-existing high blood pressure who were discharged from hospital after an admission: half with COVID-19 and half without. Baseline visit will be ≥12 weeks after discharge for measurements of blood pressure, tests of heart and blood vessel health, blood, urine and stool samples along with questionnaires on mood and quality of life. Two further study visits follow, at 12 and 18 months. This study will generate crucial evidence on the long-term impact of COVID-19 on blood pressure along with information on potential mechanisms of this effect with immediate, transferable impact on clinical practice and inform risk mitigation measures.

NCT ID: NCT05087173 Recruiting - COVID-19 Clinical Trials

Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

To evaluate the performance of an interactive chatbot and assess its effectiveness for enhancing informed decisions made by cataract patients.

NCT ID: NCT05085522 Recruiting - COVID-19 Clinical Trials

Study of the Effect of Systematic Screening of Residents and Caregivers by Nasopharyngeal Swab (RT-PCR)

INMESO
Start date: August 1, 2020
Phase:
Study type: Observational

The current COVID-19 epidemic has overwhelmed the health systems of many countries in which it has broken out, forcing various governments to institute population containment measures. Residents of medico-social institutions for the elderly are particularly at risk of developing severe forms because they have a large number of factors favoring the progression to a severe form (very advanced age, multiple comorbidities, dependence in activities of dayli life). The specificity and positive predictive value of clinical signs are not very important in this population; which makes the diagnosis even more complicated. One of the strategies to try to protect these residents, in addition to room containment and clinical surveillance, would be to carry out a systematic screening campaign of all residents and all caregivers, then to consider reorganizing the establishments with a sector "COVID +". This was announced by the French Minister of Health Olivier VERAN on 04/06/2020 from the first confirmed case of COVID-19 in an institution. However, asymptomatic subjects may have a "negative" RT-PCR test at one point but which is positive in the following days. And in this interval they would still be contagious. It is therefore not excluded that the implementation of such a screening campaign will not be effective in reducing the number of new cases of COVID-19 in medico-social institutions for the elderly

NCT ID: NCT05085262 Recruiting - Clinical trials for COVID-19 Respiratory Infection

Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19)

Start date: July 1, 2020
Phase:
Study type: Observational

The coronavirus disease of 2019 (COVID-19) has affected over 2.4 million individuals worldwide and has resulted in >171,000 deaths. Cardiovascular disease (CVD) is an important contributor to death in these patients. Those who develop cardiac injury during infection have a 4-fold increased risk of death. Furthermore, pre-existing CVD or cardiovascular risk factors (e.g. diabetes, hypertension) are associated with worse outcomes. Given the recent emergence of this disease, there is limited understanding of: (i) the risk factors for cardiovascular events, (ii) blood biomarkers for early recognition, and drug targeting, of patients at risk of adverse outcomes, and (iii) the short term subclinical and clinical cardiovascular manifestations in those who survive to discharge.

NCT ID: NCT05085145 Recruiting - COVID-19 Clinical Trials

Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV

Start date: September 1, 2021
Phase: Phase 4
Study type: Interventional

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020. Patients with HIV may be at higher risk than those without HIV for coronavirus disease 2019 (COVID-19). At present, limited data are available on the safety and immunogenicity of coronavirus vaccine for patients with HIV.

NCT ID: NCT05084976 Recruiting - Clinical trials for Mechanical Ventilation Complication

Parental Perception of COVID 19 Vaccine in Technology Dependent Patients

Start date: September 23, 2021
Phase:
Study type: Observational

This study involves conducting a telephonic or in person survey regarding parental perception and attitudes about vaccinating their "technology dependent" child with the COVID 19 vaccination. "Technology dependent" includes tracheostomy dependence, artificial ventilator dependence and non invasive mechanical ventilation dependence. This population is vulnerable since most of them have underlying lung disease and chronic respiratory failure and requiring respiratory equipment to help them breathe. They are particularly vulnerable to respiratory infections. They are considered high risk for developing severe COVID 19 illness. Despite this population's high risk for morbidity and mortality from respiratory viral infections, we hypothesize that only 50% of the parents are still vaccine hesitant.

NCT ID: NCT05084950 Recruiting - COVID-19 Clinical Trials

Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

MonaVacc
Start date: July 1, 2021
Phase:
Study type: Observational

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.